Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsProtein particles are assemblies built up of native or denatured proteins that exert a negative impact on manufacturability, safety, stability, titers, solubility, and immunogenicity of biologics in general. Protein aggregation remains a major focus of the production of antibody medicines. Therefore, monitoring protein aggregation in vivo and in vitro is essential to understand the molecular mechanism of various different diseases and to identify drug candidates capable of modulating protein aggregation. As an experienced supplier in the manufacturability assessment, Creative Biolabs provides a suite of high-quality services regarding predicting, monitoring, and reducing the aggregation propensity of drug candidates, based on the recognition of aggregation-prone regions (APRs) and their contribution to the thermodynamic stability of proteins.
Protein aggregation and long-term cellular persistence of aggregates are associated with many pathological conditions, including several neurodegenerative disorders (e.g. Alzheimer's (AD), Huntington's (HD) and Parkinson's (PD) diseases). The aggregation propensity of proteins is thought of being controlled to a large extent by the physicochemical properties of polypeptides encoded in the primary sequence.
Fig.1 Scheme of protein folding and misfolding/aggregation. (Gregoire, 2012)
As well, protein deposition is a common phenomenon during recombinant expression in microorganisms, such as fungi and bacteria. Intriguingly, the aggregates formed in these simple organisms resemble those involved in the onset of the aforementioned diseases. They’re all linked to the structure of protein self-assembly into β-sheet enriched amyloid-like formats. And β-aggregation is a process of association of proteins, primarily through the formation of intermolecular β-sheets by short APRs of the polypeptide sequence.
Protein aggregation is one of the main issues in biopharmaceutical production, storage, delivery, and formulation. Numerous physiochemical and environmental factors could perturb correctly folded conformation or inhibit correct protein folding, resulting in protein misfolding and aggregation. The abnormally increased misfolded proteins create an overloaded or damaged protein degradation system leading to intracellular aggregate formation. However, the misfolding and aggregate formation of biologics, such as α-glucosidase, α-galactosidase, angiopoietin-1, and antithrombin III within mammalian cells are still obstacles in completing high yield production of biopharmaceuticals.
Fig.2 The reduction of antibody aggregation strategy. (Van Der Kant, 2017)
On the one hand, Creative Biolabs has developed a wide range of simple, high-sensitivity methods to enable monitoring protein aggregation in cultured cells, including mammalian cells, yeast, and bacteria. These strategies are useful not only for defining optimal storage formulations for proteins but also for screening of compounds that promote or inhibit protein aggregation.
On the other hand, our scientists have achieved the optimization of cell culture medium composition and environmental factors in order to reduce intracellular aggregate formation. With advancements in molecular & cell biology techniques, we’re able to rationally design variants, according to APRs, that display a marked decrease in aggregation propensity or to identify less aggregation-prone variants of proteins by high-throughput screening of mutants. The data derived from these approaches can significantly lower liabilities in novel therapeutic proteins, guiding a more efficient path to clinical research. Moreover, we also provide different bioinformatic algorithms to exploit related features to predict protein deposition by identifying and quantifying APRs within a given sequence.
Protein aggregation has attracted great attention in recent years, which is a critical propensity to consider in the production and formulation of biologics. Reducing protein aggregation is accompanied by an increase in expression titer, showing that reduction in aggregation propensity is beneficial to the overall development process. As a well-known expert in the world, Creative Biolabs offers multiple proven strategies and comprehensive assays for monitoring and reduction of aggregation propensity, together with many other experimental manufacturability optimization assays for drug candidates. If you’re interested in our services, please don’t hesitate to contact us.
References
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
